Journal of Cardiac Failure
Volume 14, Issue 8 , Pages 695-702, October 2008

Alveolar Gas Diffusion Abnormalities in Heart Failure

  • Marco Guazzi, MD, PHD, FACC

      Affiliations

    • Corresponding Author InformationReprint requests: Marco Guazzi, MD, PhD, FACC, University of Milano, Cardiology Division, San Paolo Hospital, Via A. di Rudinì, 8, 20142 Milano, Italy.

Cardiopulmonary Unit, University of Milano, San Paolo Hospital, Milano, Italy

Received 26 January 2008; received in revised form 2 May 2008; accepted 2 June 2008. published online 21 July 2008.

Abstract 

In heart failure (HF), development of pressure or volume overload of the lung microcirculation elicits a series of structural adaptations, whose functional correlate is an increased resistance to gas transfer across the alveolar-capillary membrane. Acutely, hydrostatic mechanical injury causes endothelial and alveolar cell breaks, impairment of the cellular pathways involved in fluid filtration and reabsorption, and resistance to gas transfer. This process, which is reminiscent of the so-called alveolar-capillary stress failure, is generally reversible. When the alveolar membrane is chronically challenged, tissue alterations are sustained and a typical remodeling process may take place that is characterized by fixed extracellular matrix collagen proliferation and reexpression of fetal genes. Remodeling leads to a persistent reduction in alveolar-capillary membrane conductance and lung diffusion capacity. Changes in gas transfer not only reflect the underlying lung tissue damage but also bring independent prognostic information and may play a role in the pathogenesis of exercise limitation and ventilatory abnormalities. They are not responsive to fluid withdrawal by ultrafiltration and tend to be refractory even to heart transplantation. Some drugs can be effective that modulate lung remodeling (eg, angiotensin-converting enzyme inhibitors, whose impact on the natural course of cardiac remodeling is well known) or that increase nitric oxide availability and nitric oxide-mediated pulmonary vasodilation (eg, type 5 phosphodiesterase inhibitors). This review focuses on the current knowledge of these topics.

Key Words: Alveolar gas diffusion, exercise capacity, heart failure, lung function

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This report was supported by the Monzino Foundation, Milano, Italy.

 No conflict of interest exists.

PII: S1071-9164(08)00179-6

doi:10.1016/j.cardfail.2008.06.004

Journal of Cardiac Failure
Volume 14, Issue 8 , Pages 695-702, October 2008